An Impella update, another TAVI vs SAVR trial, two studies on angina and PCI, another null substudy from REVIVED-BCIS, and semaglutide are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Impella Update
- CHRIP BCIS 3 https://classic.clinicaltrials.gov/ct2/show/NCT05003817
- Danger-Shock Podcast https://www.medscape.com/viewarticle/1000675
II. TAVI vs SAVR
- Notion 2 Trial EHJ https://doi.org/10.1093/eurheartj/ehae331
- DEDICATE-DZHK6
III. Angina and PCI
- Orbita 2 Sub-analysis
- Orbita Star https://www.jacc.org/doi/10.1016/j.jacc.2024.04.001
IV. Complete Revascularization
- Main REVIVED trial https://www.nejm.org/doi/full/10.1056/NEJMoa2206606
- JACC Substudy https://www.jacc.org/doi/10.1016/j.jacc.2024.04.043
V. Semaglutide
Semaglutide CV Benefits Irrespective of Weight Loss: 4-Year SELECT Data
https://www.medscape.com/viewarticle/semaglutide-cv-benefits-irrespective-weight-loss-4-year-2024a100095z
- Nature Med substudy https://www.nature.com/articles/s41591-024-02996-7
- SELECT Main paper https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
